Melville, NY, (December 21, 2016) Population Diagnostics – a global leader in gene discovery for complex disease announced today that it is changing its corporate name to Population Bio. The name change reflects the company's broader commitment to precision medicine and its expertise in driving the innovations needed to shape the future of drug development and predictive diagnostics. The new name is effective immediately.
"The new name, Population Bio, better reflects our corporate mission of uncovering new truths and insights about health and disease that are the key to winning the race in precision medicine," said Jim Chinitz, CEO of Population Bio. "As a company with its roots in genomic technology, we are committed to delivering breakthroughs that will be at the heart of the next generation of therapeutics and diagnostics."
Novel genetic information uncovered by Population Bio’s platform enables precision medicine for our strategic partners by:
- Inspiring new and targeted drug development strategies
- Catalyzing new and novel diagnostics for early, pre-symptomatic detection of disease for earlier therapeutic intervention
- Developing predictive tests for drug efficacy and safety
- Rescuing drugs from failed clinical trials and repurposing approved drugs
ABOUT POPULATION BIO
Population Bio, Inc. (PB) is a privately held global gene discovery company leading the field of precision medicine. Built on extensive intellectual property, PB is empowering pharmaceutical companies to develop targeted therapies and companion diagnostics faster and more cost effectively. Addressing critical health concerns, PB’s patented technology is currently in clinical studies, collaborations and partnerships addressing complex neurological diseases, such as Autism, Parkinson’s and Alzheimer’s, in addition to other common conditions having a genetic component such as endometriosis and peanut allergy.
For more information, contact:
Regina M Reynolds,